Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Polycythemia Vera - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 14 Sep 17

The "Polycythemia Vera - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 3 and 2 respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Polycythemia Vera - Overview
  3. Polycythemia Vera - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Polycythemia Vera - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Polycythemia Vera - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • Gilead Sciences Inc
  • Italfarmaco SpA
  • Nerviano Medical Sciences Srl
  • PharmaEssentia Corp

For more information about this report visit https://www.researchandmarkets.com/research/h7wqnv/polycythemia_vera

View source version on businesswire.com: http://www.businesswire.com/news/home/20170914006032/en/

Business Wire
www.businesswire.com

Last updated on: 14/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.